Evidence map›Paper›PMID 39304428›Full record

SynthesisEuropean urology2025

Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.

Wee Loon Ong, Tahmineh Romero, Soumyajit Roy, John Nikitas, David Joseph, Almudena Zapatero, Shawn Malone, Scott C Morgan, Michael L Steinberg, Luca F Valle and 15 more

Registry-linked trialAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07460726 (A Single Arm Prospective Study to Investigate the Impact of Stereotactic Body Radiation Therapy), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07460726 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Single Arm Prospective Study to Investigate the Impact of Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) on Sexual Dysfunction in Unfavorable Intermediate Risk Prostate Cancer

Typeobservational_patient_registrySponsorCancerCare ManitobaRan2026 to 2029Enrolled130ConditionsProstate Cancer (Adenocarcinoma), Erectile Abnormalities, Sexual Dysfunction MaleArmsSBRT combined with ADT
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. The contemporary management of prostate cancer.CA: a cancer journal for clinicians
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Wee Loon OngAlfred Health Radiation Oncology, Monash University, Melbourne, Australia.
Tahmineh RomeroDivision of General Internal Medicine and Health Services Research, University of California-Los Angeles, Los Angeles, CA, USA.
Soumyajit RoyDepartment of Radiation Oncology, Rush University Medical Centre, Chicago, IL, USA.
John NikitasDepartment of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA.
David JosephDepartment of Medicine and Surgery, University of Western Australia, Perth, Australia.
Almudena ZapateroDepartment of Radiation Oncology, Health Research Institute, Hospital Universitario de la Princesa, Madrid, Spain.
Shawn MaloneDepartment of Radiology, Radiation Oncology and Medical Physics, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Canada.
Scott C MorganDepartment of Radiation Oncology, University Hospitals Seidman Cancer Centre, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Michael L SteinbergDepartment of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA.
Luca F ValleDepartment of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA.
Nicholas G ZaorskyDepartment of Radiation Oncology, University Hospitals Seidman Cancer Centre, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Ting Martin MaDepartment of Radiation Oncology, University of Washington, Seattle, WA, USA.
Matthew B RettigDepartment of Medical Oncology, University of California-Los Angeles, Los Angeles, CA, USA.
Nicholas NickolsDepartment of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA.
Tommy JiangDepartment of Urology, University of California-Los Angeles, Los Angeles, CA, USA.
Robert E ReiterDepartment of Urology, University of California-Los Angeles, Los Angeles, CA, USA.
Sriram V EleswarapuDepartment of Urology, University of California-Los Angeles, Los Angeles, CA, USA.
Xavier MaldonadoHospital Universitari Vall d'Hebron, Barcelona, Spain.
Yilun SunDepartment of Radiation Oncology, University Hospitals Seidman Cancer Centre, Case Western Reserve University School of Medicine, Cleveland, OH, USA; Department of Population Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.
Paul L NguyenDepartment of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jeremy L MillarAlfred Health Radiation Oncology, Monash University, Melbourne, Australia.
Jarad M MartinDepartment of Radiation Oncology, Calvary Mater Newcastle Hospital, University of Newcastle, Newcastle, Australia.
Daniel E SprattDepartment of Radiation Oncology, University Hospitals Seidman Cancer Centre, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Amar U KishanDepartment of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA. Electronic address: aukishan@mednet.ucla.edu.
MARCAP Consortium Investigators

Funding

Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu · 2014 to 2026
$27.6M
Integrative Cancer Scholars Training GrantT32CA009213 · NCI · UNIVERSITY OF ARIZONA · PI CAREW, JENNIFER S, CURIEL-LEWANDROWSKI, CLARA · 1985 to 2024
$8.6M
Reducing toxicity from prostate cancer radiotherapy through genetics and technologyR37CA292795 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Amar U Kishan · 2024 to 2026
$1.1M
NCI NIH HHS P50 CA186786NCI NIH HHS R37 CA292795NCI NIH HHS T32 CA009213
6 · The paper itself

Abstract

BACKGROUND AND

objectiveTime to testosterone recovery (TR) following androgen deprivation therapy (ADT) with gonadotropin-releasing hormone agonists varies widely. We evaluate TR kinetics and the oncological impact of an effective castration period in patients receiving definitive radiotherapy and ADT for prostate cancer.

methodsWe obtained individual patient data from randomized controlled trials of radiotherapy with ADT and prospectively collected serial testosterone data from the MARCAP Consortium. We estimated the times to noncastrate TR (>1.7 nmol/l) and nonhypogonadal TR (>8.0 nmol/l) were estimated for each prescribed ADT duration, and developed corresponding nomograms. The association between effective castration period and metastasis-free survival (MFS) for any given ADT duration was evaluated via multivariable Cox regression. We conducted cubic spline analyses to assess nonlinear associations. KEY FINDINGS AND LIMITATIONS: We included 1444 men from five trials in the analysis, of whom 115 received 4 mo, 880 received 6 mo, 353 received 18 mo, 36 received 28 mo, and 60 received 36 mo of ADT. Times to noncastrate TR and to nonhypogonadal TR varied considerably by ADT duration. Higher baseline testosterone and lower age were associated with a higher likelihood of TR (p < 0.001 for both). Effective castration period was not linearly associated with MFS for any ADT duration on Cox regression. Cubic spline analysis revealed that the optimal effective castration period for an MFS benefit was 10.6 mo for men who received 6 mo of ADT and 18 mo for men who received 18 mo of ADT. CONCLUSIONS AND CLINICAL IMPLICATIONS: Time to TR varies according to the ADT duration, baseline testosterone, and age. The relationship between effective castration period and MFS may be nonlinear, with a longer effective castration period being helpful for men receiving 6 mo of ADT.

Indexed as

Androgen AntagonistsProstatic NeoplasmsTestosteroneCombined Modality TherapyHumansMaleRandomized Controlled Trials as TopicTime FactorsAndrogen AntagonistsTestosteroneAndrogen deprivation therapyProstate cancerRadiotherapyTestosterone recovery

Identifiers

PMID39304428
PMCPMC12885072

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.